Homology Medicines, Inc.

NasdaqGS:FIXX 株式レポート

時価総額:US$54.3m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Homology Medicines マネジメント

マネジメント 基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

最高経営責任者

n/a

報酬総額

CEO給与比率n/a
CEO在任期間no data
CEOの所有権n/a
経営陣の平均在職期間データなし
取締役会の平均在任期間6.2yrs

経営陣の近況

Recent updates

Homology Medicines (NASDAQ:FIXX) Will Have To Spend Its Cash Wisely

Nov 16
Homology Medicines (NASDAQ:FIXX) Will Have To Spend Its Cash Wisely

Homology Medicines appoints new CEO, chairperson

Sep 06

Homology announces peer-reviewed preclinical data publication on its AAVHSC16 capsid

Jul 05

Here's Why We're Watching Homology Medicines' (NASDAQ:FIXX) Cash Burn Situation

Jan 28
Here's Why We're Watching Homology Medicines' (NASDAQ:FIXX) Cash Burn Situation

Homology Medicines: In Vivo Gene Therapy Platform With Delayed Lead Trial Coming Back Online

Oct 22

We Think Homology Medicines (NASDAQ:FIXX) Can Afford To Drive Business Growth

Sep 18
We Think Homology Medicines (NASDAQ:FIXX) Can Afford To Drive Business Growth

Growth Investors: Industry Analysts Just Upgraded Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts By 20%

Aug 14
Growth Investors: Industry Analysts Just Upgraded Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts By 20%

Industry Analysts Just Made A Sizeable Upgrade To Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts

May 22
Industry Analysts Just Made A Sizeable Upgrade To Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts

Homology Medicines (FIXX) Investor Presentation - Slideshow

May 05

Homology Medicines (NASDAQ:FIXX) Is In A Good Position To Deliver On Growth Plans

Apr 17
Homology Medicines (NASDAQ:FIXX) Is In A Good Position To Deliver On Growth Plans

Are Institutions Heavily Invested In Homology Medicines, Inc.'s (NASDAQ:FIXX) Shares?

Mar 13
Are Institutions Heavily Invested In Homology Medicines, Inc.'s (NASDAQ:FIXX) Shares?

Homology Medicines' (NASDAQ:FIXX) Stock Price Has Reduced 25% In The Past Year

Feb 03
Homology Medicines' (NASDAQ:FIXX) Stock Price Has Reduced 25% In The Past Year

CEO(最高経営責任者

Homology Medicines CEOがいない、あるいは彼らに関するデータがない。


取締役

名称ポジション在職期間報酬所有権
Saswati Chatterjee
Co-Founder & Member of Scientific Advisory Boardno dataデータなしデータなし
Steven S. Gillis
Independent Director8.2yrsUS$69.06k0%
$ 0
Matthew Patterson
Independent Director6.2yrsUS$68.56k0%
$ 0
Beverly Davidson
Chairman of Scientific Advisory Board6.2yrsデータなしデータなし
Mary Thistle
Independent Director6yrsUS$76.06k0%
$ 0
Mason Freeman
Member of Scientific Advisory Boardno dataデータなしデータなし
Morton Cowan
Member of Scientific Advisory Boardno dataデータなしデータなし
Stephen Elledge
Member of Scientific Advisory Boardno dataデータなしデータなし
Arthur Tzianabos
Chairman of the Board7.9yrsUS$1.67m0.22%
$ 120.4k
Jeffrey Poulton
Lead Independent Director3.7yrsUS$68.56k0%
$ 0
Alise Reicin
Independent Director4.7yrsUS$68.22k0%
$ 0
Hans-Peter Kiem
Member of Scientific Advisory Boardno dataデータなしデータなし

6.2yrs

平均在職期間

62yo

平均年齢

経験豊富なボード: FIXXの 取締役会経験豊富 であると考えられます ( 6.2年の平均在任期間)。